Auvelity (Dextromethorphan-Bupropion) and Suicidal Thoughts
Auvelity (dextromethorphan-bupropion) carries an FDA boxed warning for increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults up to age 24. 1
Understanding the Risk
The medication contains bupropion, which like all antidepressants, has been associated with increased suicidal ideation in younger populations. The FDA mandates close monitoring for this serious adverse effect 1, 2.
Specific Risk Profile
- Highest risk period: First few months of treatment and when doses are changed 1
- Age-related risk: Most pronounced in patients under 24 years old 3
- Absolute risk: Pooled data across antidepressants show suicidal ideation occurs in approximately 1% of treated patients versus 0.2% on placebo 4
Critical Monitoring Requirements
You must assess patients within 1-2 weeks of starting Auvelity and continue regular monitoring throughout treatment. 5
Warning Signs to Monitor
Watch for these symptoms that may indicate worsening depression or emerging suicidality:
- New or worsening suicidal thoughts or behaviors
- Agitation, restlessness, or irritability
- Panic attacks or severe anxiety
- Insomnia or sleep disturbances
- Acting aggressive, angry, or violent
- Impulsive or dangerous behavior
- Extreme increase in activity or talking (mania)
- Unusual changes in behavior or mood 1
Clinical Context: Bupropion's Safety Profile
Importantly, bupropion itself has demonstrated relatively favorable safety regarding suicidality compared to other antidepressants. Studies of bupropion for smoking cessation have reported mood changes including depression and mania, but large trials of naltrexone-bupropion combinations showed no increased frequency of depression, suicidality, or mood disorders 3, 6.
Comparative Evidence
- SSRIs as a class show increased risk for nonfatal suicide attempts compared to placebo (odds ratio 1.57-2.25) 5
- Bupropion monotherapy studies have not demonstrated increased suicidality rates 6
- The boxed warning applies to all antidepressants as a class effect, not specific evidence for this combination 1
Contraindications and High-Risk Scenarios
Do not prescribe Auvelity to patients with:
- Active suicidal ideation or recent suicide attempts
- Seizure disorders or eating disorders (bulimia, anorexia)
- Concurrent MAOI use or within 14 days of MAOI discontinuation
- Untreated bipolar disorder (screen all patients before initiating) 1
Practical Management Algorithm
Pre-treatment screening: Assess for bipolar disorder history, current suicidality, seizure risk, and substance use 1
Initial monitoring: Schedule follow-up within 1-2 weeks of starting treatment 5
Ongoing surveillance: Continue regular assessments, especially during dose adjustments
Patient/family education: Provide clear instructions to report any mood changes, agitation, or suicidal thoughts immediately 1
Discontinuation if needed: Stop Auvelity immediately if suicidal thoughts emerge or worsen 1
Important Caveats
The case report of a suicide attempt by overdose with approximately 30 tablets of dextromethorphan-bupropion highlights the importance of prescribing limited quantities to at-risk patients and maintaining vigilant monitoring 7. The patient required intubation and intensive care, underscoring the serious consequences of overdose.
The benefit-risk calculation must weigh the substantial benefits of treating depression against the small but real risk of increased suicidal ideation, particularly in younger patients. 6